Figure 1.

Graphical analysis of white blood cell count, absolute neutrophil count, platelets and hemoglobin at diagnosis, with escalating doses of ruxolitinib, and at the time of progression. Ruxolitinib resulted in a rapid and significant reduction in white blood cells (10⁹/L), absolute neutrophil count (10⁹/L) as well as improvement in platelets (10⁹/L) and stabilization of hemoglobin (g/dL). At disease progression there was an increase in the white blood cells and neutrophils, mitigated by hydroxyurea as well as a decline in platelets and hemoglobin.